Integumen PLC (LON:SKIN) said its subsidiary, Labskin has launched the world’s first remote clinical skin trials platform.
The AIM-listed group said the platform will harvest a human volunteer’s skin and transport it to the Labskin laboratory to be transplanted onto laboratory-grown skin, creating an exact replica of the human volunteer's skin microflora without them leaving their home.
WATCH: Integumen's Gerry Brandon details new £3mln facility for Labskin and Covid-19 expansion
Integumen also said another subsidiary, software and artificial intelligence (AI) group Rinocloud, has built a remote clinical skin trial platform which allows trials to happen ethically, efficiently with all protocols being followed and distantly controlled, with data stored according to GDPR guidelines. The platform also allows swapping to be done under supervision in the volunteer’s home, without the need for in-person contact.
The company noted that Labskin and Rinocloud created the platform as an extension to the Labskin AI virtual disease modelling development program that it said had “transformed” its business model over the last 24 months.
"With the spread of [coronavirus] continuing to accelerate globally, the science and AI teams advanced this development over the last 3 months to create a virtual Clinical Research platform that has been disrupted by the lockdown”, Integumen chief executive Gerard Brandon said in a statement.
“This has increased access to immune-suppressed, aged or infirm human volunteers without placing them at risk. It is being further adapted to undertake skin trials for individual consumers for cosmetic, skin disease diagnostics. I look forward to updating the market very soon on progress with Integumen and other [coronavirus] related programmes", he added.
Integumen shares were 0.1% lower at 2p in late-morning trading on Friday.
--Adds share price--